Vaccine hesitancy and equity: lessons learned from the past and how they affect the COVID-19 countermeasure in Indonesia

Globalization and Health, Journal Year: 2024, Volume and Issue: 20(1)

Published: Feb. 6, 2024

Abstract Introduction Indonesia has made progress in increasing vaccine coverage, but equitable access remains challenging, especially remote areas. Despite including vaccines the National Immunization Program (NIP), coverage not met WHO and UNICEF targets, with childhood immunization decreasing during COVID-19 pandemic. vaccination also experienced hesitancy, slowing efforts to end Scope This article addresses issue of hesitancy its impact on initiatives amidst utilizes framework analyze previous outbreaks vaccine-preventable diseases their underlying causes, ultimately providing recommendations for addressing current situation. The analysis considers differences between pre-pandemic circumstances present implementation basic advanced strategies. Key findings conclusion Vaccine is a significant challenge pandemic, public health campaigns community engagement are needed promote acceptance uptake. Efforts address trust healthcare systems increase likelihood individuals seeking preventive services. requires comprehensive, culturally sensitive approach that local contexts realities. Strategies should be tailored specific cultural societal monitored evaluated.

Language: Английский

---

Preparation, pungency and bioactivity transduction of piperine from black pepper (Piper nigrum L.): A comprehensive review

Food Chemistry, Journal Year: 2024, Volume and Issue: 456, P. 139980 - 139980

Published: June 5, 2024

Language: Английский

---

Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study

Human Vaccines & Immunotherapeutics, Journal Year: 2023, Volume and Issue: 19(1)

Published: Jan. 2, 2023

High and equitable COVID-19 vaccination coverage is important for pandemic control prevention of health inequity. However, little known about socioeconomic correlates booster coverage. In this cross-sectional study all Norwegian adults in the national program (N = 4,190,655), we use individual-level registry data to examine by levels household income education primary (≥2 doses) (≥3 against COVID-19. We stratify analyses age groups with different recommendations report relative risk ratios (RR) 25 August 2022. 18-44 y group, individuals highest vs. lowest had 94% 79% (adjusted RR (adjRR) 1.15, 95%CI 1.14-1.15) 67% 38% (adjRR 1.55, 95% CI 1.55-1.56), while 81% 1.10, 1.10-1.10) 60% 43% 1.23, 1.22-1.24). ≥45 96% 92% 1.02, 1.02-1.02) 88% 80% 1.09, 1.09-1.09), 98% 82% 1.16, 1.16-1.16) 64% 1.33, 1.33-1.34). conclusion, document large inequalities coverage, especially vaccination, even though was free-of-charge. The results highlight need tailor information target underserved vaccination.

Language: Английский

---

The Discovery of inhibitors of the SARS-CoV-2 S protein through computational drug repurposing

Computers in Biology and Medicine, Journal Year: 2024, Volume and Issue: 171, P. 108163 - 108163

Published: Feb. 14, 2024

SARS-CoV-2 must bind its principal receptor, ACE2, on the target cell to initiate infection. This interaction is largely driven by receptor binding domain (RBD) of viral Spike (S) protein. Accordingly, antiviral compounds that can block RBD/ACE2 interactions constitute promising agents. To identify such molecules, we performed a virtual screening Selleck FDA approved drugs and database Natural Products using multistep computational procedure. An initial set candidates was identified from an ensemble docking process representative structures determined analysis four 3 μ s molecular dynamics trajectories complex. Two procedures were used construct including standard pharmacophore guided The subsequently subjected sieving reduce number be tested experimentally, increasingly demanding procedures, calculation free energy computed MMPBSA MMGBSA methods. After process, final list 10 proposed, which purchased ex-vivo. results estradiol cypionate telmisartan as inhibitors entry into cells. Our findings demonstrate methodology presented here enables discovery targeting viruses for high-resolution are available.

Language: Английский

---

The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19

Revista Española de Quimioterapia, Journal Year: 2023, Volume and Issue: 36(5), P. 507 - 515

Published: June 12, 2023

Objectives. Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of coronavirus disease (COVID-19) as we move from a pandemic an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection infection in addition severe illness hospitalisation. Here present review evidence base for new COVID-19 vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U), results expert consensus. Materials methods. The committee consisted Spanish experts medicine, family paediatrics, immunology, microbiology, nursing, veterinary medicine. Consensus was achieved using 4-phase process consisting face-to-face meeting during which scientific reviewed, online questionnaire elicit opinions on value PHH-1V, second update discuss evolution epidemiological situation, vaccine programmes final at consensus achieved. Results. agreed constitutes valuable novel development vaccination aimed towards protecting population disease. based broad-spectrum efficacy established emerging variants, potent response, good safety profile. physicochemical properties formulation facilitate handling storage appropriate uptake. Conclusions. properties, formulation, immunogenicity low reactogenic profile confirm appropriateness this vaccine.

Language: Английский

---

The survey of vaccination hesitancy among the residents in Jinan

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(1), P. e0309431 - e0309431

Published: Jan. 3, 2025

Introduction Vaccination is an important way to prevent disease, but vaccine hesitancy will impact coverage and indirectly affect health. This study aims survey the status of among adults in Jinan. Methods A cross-sectional was conducted using scale parents children teenagers at hospitals Jinan, China. We described attitude vaccination through dimensions confidence (items: L1-L7) risk (items:L8-L10).The participants be regarded as lacking if score over 21 items (L1-L7), consider a “Risk” 9 (L8-L10). Using chi-square test analyse differences between different participants. Results 202 individuals were enrolled, most respondents (88.70%) agreed that vaccines are for their child’s 33.50% strongly new carried more risks than older vaccines. The average lack 11±0.25. 9.92±0.04. Participants aged below 30 years, females, those with lower education, without medical workers family concerned about Conclusions confident vaccination. But they also knowledge may led have vaccinations.

Language: Английский

---

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 22, 2025

Introduction Baricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which associated with clinical improvement in non-severe COVID-19 patients. But severe patients, the effectiveness baricitinib still controversial. Methods A propensity score-matched retrospective study was conducted to evaluate patients requiring invasive mechanical ventilation (IMV). Results total number 48 treated were included, assigned control group by score matching. The mean ages high both (baricitinib vs. group: 78.80 ± 9.04 82.57 9.27), most unvaccinated (62.5% 66.7%. had higher proportion hypertension (73.9% 45.5%, p = 0.006). Control level creatine kinase-myocardial band (247.50 104.50, 0.021). Patients more likely receive nirmatrelvir/ritonavir (39.6% 16.7%, 0.017) intravenous immunoglobin (14.6% 0, 0.007). significantly lower all-cause 28-days mortality than (72.9% 89.6%, 0.004). Conclusion present revealed reduced on IMV. treating IMV needs be further investigated through future studies.

Language: Английский

---

Investigating practices and difficulties in communicating with patients about COVID-19 vaccination among healthcare workers in Italy

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 20, 2025

The aims of this cross-sectional study were to understand the healthcare workers' (HCWs) practices and difficulties in communicating with patients about COVID-19 vaccinations, investigate factors associated, identify targets improve efficacy immunization strategy. Questionnaires administered between November 2021 March 2022 three centers Italy. More than half HCWs (56.8%) reported always recommend vaccination their patients, recommendations for other vaccinations provided by 50.4% participants. Physicians/medical residents, males, those who recommended more likely vaccination. participants' perception impact sources information on patients' knowledge vaccination, explored using a ten-point Likert-type scale, resulted mean value 6.3 7.9, respectively. A higher level regarding was be found among nurses/midwives younger HCWs. It is important reduce HCWs' perceived gap supporting them through health policy engaging increasing uptake rates.

Language: Английский

---

Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults

Vaccine, Journal Year: 2025, Volume and Issue: 54, P. 127048 - 127048

Published: March 30, 2025

Language: Английский

---

Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 424 - 424

Published: April 17, 2025

Vaccination has been instrumental in curbing the transmission of SARS-CoV-2 and mitigating severity clinical manifestations associated with COVID-19. Numerous COVID-19 vaccines have developed to this effect, including BioNTech-Pfizer Moderna’s mRNA vaccines, as well adenovirus vector-based such Oxford–AstraZeneca. However, emergence new variants subvariants SARS-CoV-2, characterized by enhanced transmissibility immune evasion, poses significant challenges efficacy current vaccination strategies. In review, we aim comprehensively outline landscape emerging concern (VOCs) sub-lineages that recently surfaced post-pandemic years. We assess effectiveness existing their booster doses, against these subvariants, BA.2-derived sub-lineages, XBB BA.2.86 (Pirola). Furthermore, discuss latest advancements vaccine technology, multivalent pan-coronavirus approaches, along development several next-generation coronavirus exosome-based, virus-like particle (VLP), mucosal, nanomaterial-based vaccines. Finally, highlight key critical areas for future research address evolving threat develop strategies combating viral threats, thereby improving preparedness pandemics.

Language: Английский

---